CD44 and breast carcinoma: Additionally, HA-DOX-CDDP micelles showed higher cellular uptake and stronger growth inhibition compared to free drugs in 4T1 (CD44+) breast cancer cells, while no significant differences were observed in NIH-3T3 (CD44−) control cells.